Healthcare Stocks in Penny Space- IPD, ANP

Blog Feb 13, 2020

 Healthcare is a lucrative and dynamic sector for investors, and amid ambiguity and fluctuating stock market environment, Australia’s healthcare system stands out as one of the top sectors for investment purpose. Investment in healthcare s...

Noxopharm Seeks to Bring Veyonda® to Market as a First-in-class Drug to Boost the Effectiveness of Radiation Therapy in Prostate Cancer

News Feb 10, 2020

Noxopharm Limited (ASX:NOX), an Australian clinical stage biotechnology company with its focus on oncology, is known for developing a novel, potentially transformative and industry disruptive cancer drug treatment using its lead candidate, Veyonda&re...

A Flip Through Imugene’s December 2019 Quarterly 4C Report

News Feb 05, 2020

Australia-headquartered clinical stage immuno-oncology player, Imugene Limited (ASX:IMU) has recently released its Quarterly 4C report on the ASX, highlighting its key activities undertaken during December 2019 quarter. Imugene continued to focus on ...

SUDA Delivered Strong Performance in 2Q FY20, A Glimpse of Operational Highlights

News Feb 05, 2020

Continuing its practice of making robust quarterly progress, the oro-mucosal drug delivery player of Australia, SUDA Pharmaceuticals Limited (ASX: SUD) is out with another solid quarterly report for the December 2019 quarter. SUDA is a world leader ...

Prescient Therapeutics December 2019 Quarterly Update Unveiling Strong Clinical Progress

News Feb 03, 2020

Prescient Therapeutics Limited (ASX: PTX), an Australian based clinical-stage Oncology company, dedicated towards the treatment of an array of challenging cancers with significant unmet need has recently reported operating highlights and financi...

Imugene Announced Completion of GMP manufacturing and Toxicology Studies for PD1-Vaxx

Australian Shares Jan 31, 2020

Australia-headquartered clinical stage immuno-oncology player, Imugene Limited (ASX:IMU) has hit a new milestone, with the completion of GMP manufacturing and preclinical toxicology studies for its B-cell cancer immunotherapy - PD1-Vaxx. These pre-c...

Prescient’s “BASKET” Approach Transforming Future Clinical Trials

Prescient Therapeutics Limited (ASX: PTX) Jan 30, 2020

Clinical-stage oncology company, headquartered in Melbourne, Australia, Prescient Therapeutics (ASX:PTX) (“Prescient”), develops personalised medicines to defeat cancer taking an approach to address mutations that cause cancer. Current &...

SUDA Pharmaceuticals Signed Two Major Deals with Sanofi and Ordesa

Australian Shares Jan 21, 2020

In a significant development, Australia-based pharmaceutical player SUDA Pharmaceuticals Limited (ASX: SUD) has recently signed deals with two renowned entities - Sanofi Aventis Groupe and Laboratorios Ordesa S.L. The deals followed the agreement fi...

A Smash Hit by Imugene: Received Core US Patent for HER-Vaxx

Healthcare Jan 15, 2020

It’s surely a prosperous new year for the clinical-stage immuno-oncology player, Imugene Limited (ASX:IMU) that has received core US patent in the largest pharmaceutical market of the world. The United States Patent and Trademark Office (USPTO...